Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Allo-HCT for High-Risk ALL in CR
NCT00027547Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jul 2001
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of fludarabine in acute lymphoblastic leukemia (ALL), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Disease Free Survival at 1 year and Transplant-Related Mortality at Day 200. Started Jul 2001; status: completed.
02
Drugs
fludarabine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00027547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027547.